Is Weakness In Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Is Weakness In Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
With its stock down 27% over the past three months, it is easy to disregard Shenyang Xingqi PharmaceuticalLtd (SZSE:300573). But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to Shenyang Xingqi PharmaceuticalLtd's ROE today.
过去三个月股价下跌27%,很容易忽视沈阳星期制药股份有限公司(SZSE:300573)。但如果你仔细留意,你可能会发现它强大的财务状况意味着股票有可能在长期内价值上升,因为市场通常会奖励财务状况良好的公司。特别是,我们将关注沈阳星期制药股份有限公司今日的roe。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率或roe是评估公司管理层如何有效利用公司资本的关键指标。简而言之,ROE显示每美元股东投资所产生的利润。
How Do You Calculate Return On Equity?
怎样计算ROE?
Return on equity can be calculated by using the formula:
股东权益报酬率可以使用以下公式计算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益
So, based on the above formula, the ROE for Shenyang Xingqi PharmaceuticalLtd is:
因此,基于以上公式,沈阳星期制药股份有限公司的roe为:
21% = CN¥322m ÷ CN¥1.5b (Based on the trailing twelve months to June 2024).
21% = 32200万元 ÷ 15亿元(基于截至2024年6月的过去十二个月)。
The 'return' is the profit over the last twelve months. Another way to think of that is that for every CN¥1 worth of equity, the company was able to earn CN¥0.21 in profit.
‘回报’是过去十二个月的利润。另一种思考方式是,对于每1元人民币的净资产,公司能够赚取0.21元人民币的利润。
What Has ROE Got To Do With Earnings Growth?
roe与盈利增长有何关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.
我们已经确认ROE是一个有效的判断公司未来盈利能力的指标。根据公司再投资或“保留”利润的比例及其效率来判定公司的盈利增长潜力,通常情况下,其他条件相同,具有高股权回报率和利润保留率的公司增长速度会高于这些属性缺失的公司。
Shenyang Xingqi PharmaceuticalLtd's Earnings Growth And 21% ROE
Shenyang Xingqi PharmaceuticalLtd的盈利增长和21%的roe
To start with, Shenyang Xingqi PharmaceuticalLtd's ROE looks acceptable. On comparing with the average industry ROE of 7.8% the company's ROE looks pretty remarkable. This certainly adds some context to Shenyang Xingqi PharmaceuticalLtd's exceptional 34% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.
首先,沈阳星期制药有限公司的roe看起来是可以接受的。与行业平均roe 7.8%相比,该公司的roe看起来相当不错。这无疑为沈阳星期制药有限公司过去五年看到的异常34%的净利润增长增加了一些背景。我们认为这里也可能存在其他因素。例如,该公司的派息比率较低或者被有效管理。
As a next step, we compared Shenyang Xingqi PharmaceuticalLtd's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 9.1%.
作为下一步,我们将沈阳星期制药有限公司的净利润增长与行业进行了比较,令人高兴的是,我们发现公司的增长高于行业平均增长9.1%。
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Shenyang Xingqi PharmaceuticalLtd's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
公司的价值取决于其盈利增长。投资者需要判断的是,预期的盈利增长是否已经融入股价,或者尚未融入其中。这样做将有助于他们判断股票的未来是光明还是暗淡。如果您对沈阳星期制药的估值感兴趣,请查看其市盈率与行业的比较。
Is Shenyang Xingqi PharmaceuticalLtd Efficiently Re-investing Its Profits?
沈阳星期制药是否有效地重新投资其利润?
Shenyang Xingqi PharmaceuticalLtd has a significant three-year median payout ratio of 62%, meaning the company only retains 38% of its income. This implies that the company has been able to achieve high earnings growth despite returning most of its profits to shareholders.
沈阳星期制药有显著的三年中位数分红比率为62%,意味着公司只留下38%的收入。这意味着尽管大部分利润返还股东,该公司仍能实现高盈利增长。
Moreover, Shenyang Xingqi PharmaceuticalLtd is determined to keep sharing its profits with shareholders which we infer from its long history of seven years of paying a dividend.
此外,我们可以从沈阳星期制药愿意在过去七年持续向股东分红的历史推断出,公司决心继续与股东分享利润。
Summary
总的来说,我们对伟明环保的表现非常满意。具体而言,我们喜欢公司以高回报率再投资了其利润的很大一部分。当然,这导致公司的收益大幅增长。但是,最新的行业分析师预测表明,该公司的收益预计将加速增长。
In total, we are pretty happy with Shenyang Xingqi PharmaceuticalLtd's performance. We are particularly impressed by the considerable earnings growth posted by the company, which was likely backed by its high ROE. While the company is paying out most of its earnings as dividends, it has been able to grow its earnings in spite of it, so that's probably a good sign. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
总的来说,我们对沈阳星期制药有着相当满意的表现。我们尤其对公司所公布的可观收益增长印象深刻,这可能是其高roe所支持的。虽然公司将大部分收益作为分红支付,但它仍然能够实现收益增长,所以这可能是一个好迹象。最新的行业分析师预测显示,该公司有望保持其当前的增长速度。要了解更多关于公司的最新分析师预测,请查看该公司的分析师预测可视化。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。